Singapore medtech start-up launches synthetic skin substitute
Bioactiv Matrix does not require specialised storage, allowing it to be used in areas such as disaster zones.
Singapore's medical technology startup Bioactivx has introduced a groundbreaking synthetic skin substitute called Bioactiv Matrix, designed to accelerate healing for patients with severe burns or deep abrasions. Unlike traditional substitutes, which often use animal-derived collagen, Bioactiv Matrix eschews animal products, storage requirements, and potential cultural or religious restrictions.
The innovation, granted regulatory approval by Singapore's Health Sciences Authority, can be produced via 3D-printing in the startup's new premises, making it accessible even in disaster zones. Bioactivx, spun off from A*STAR and healthcare cluster SingHealth, secured $3 million in its latest funding round led by Swiss investment firm ContInvest and Singapore venture capital firm Cocoon Capital, bringing its total funding to $4.9 million.
The company aims to expand regionally by 2027 and is pursuing FDA approval for the synthetic skin substitute. Its applications extend beyond burns, targeting chronic wounds, diabetic ulcers, and inflammatory skin conditions. Bioactivx's partnership with UltiMaker and Novatech further supports its goal of bringing this innovation to clinicians and patients globally.
Written by urgent.news from Straits Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
